PDF herunterladen
Thromb Haemost 2020; 120(09): 1240-1247
DOI: 10.1055/s-0040-1713752
Coagulation and Fibrinolysis

In Vitro Evaluation of Pro- and Anticoagulant Drugs in Children with End-Stage Liver Disease Undergoing Liver Transplantation

Maureen J. M. Werner
1   Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2   Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Jelle Adelmeijer
2   Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Vincent E. de Meijer
1   Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Ruben H. J. de Kleine
1   Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
René Scheenstra
3   Department of Pediatric Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Sander T. H. Bontemps
4   Department of Pediatric Intensive Care, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Koen M. E. M. Reyntjens
5   Department of Anesthesiology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Jan B. F. Hulscher
6   Section of Pediatric Surgery, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Robert J. Porte
1   Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2   Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
,
Ton Lisman
1   Section of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
2   Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands
› Institutsangaben Funding Research funding was obtained by the University Medical Center Groningen Transplantation Research Foundation, Groningen, the Netherlands.
› Weitere Informationen
Auch verfügbar auf
    Lizenzen und Reprints

Abstract

Background Pro- and anticoagulant drugs are commonly used in pediatric liver transplantation to prevent and treat thrombotic and bleeding complications. However, the combination of baseline hemostatic changes in children with liver disease and additional changes induced by transplantation makes this very challenging. This study aimed to analyze the efficacy of clinically available pro- and anticoagulant drugs in plasma from children undergoing liver transplantation.

Methods In vitro effects of pro- and anticoagulant drugs on thrombin generation capacity were tested in plasma samples of 20 children (≤ 16 years) with end-stage liver disease undergoing liver transplantation, and compared with 30 age-matched healthy controls.

Results Addition of pooled normal plasma had no effect in patients or controls, while 4-factor prothrombin complex concentrate increased thrombin generation in both patients and controls, with enhanced activity in patients. At start of transplantation, dabigatran and unfractionated heparin had a higher anticoagulant potency in patients, whereas 30 days after transplantation low molecular weight heparin was slightly less effective in patients. Effects of rivaroxaban were comparable between patients and controls.

Conclusion This study revealed important differences in efficacy of commonly used pro- and anticoagulant drugs in children with end-stage liver disease undergoing liver transplantation. Therefore, dose adjustments of these drugs may be required. The results of this study may be helpful in the development of urgently needed protocols for strategies to prevent and treat bleeding and thrombotic complications in pediatric liver transplantation.

Keywords

coagulation - hemostasis - liver transplantation - pro- and anticoagulant drugs - thrombosis

Supplementary Material



Publikationsverlauf

Eingereicht: 26. März 2020

Angenommen: 18. Mai 2020

Artikel online veröffentlicht:
06. Juli 2020

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Stuttgart · New York

 

  • References

  • 1 Borst AJ, Sudan DL, Wang LA, Neuss MJ, Rothman JA, Ortel TL. Bleeding and thrombotic complications of pediatric liver transplant. Pediatr Blood Cancer 2018; 65 (05) e26955
    CrossrefPubMedSuche in Google Scholar
  • 2 Ziaziaris WA, Darani A, Holland AJA. , et al. Reducing the incidence of hepatic artery thrombosis in pediatric liver transplantation: effect of microvascular techniques and a customized anticoagulation protocol. Pediatr Transplant 2017; 21 (04)
    CrossrefPubMedSuche in Google Scholar
  • 3 Kamran Hejazi Kenari S, Mirzakhani H, Eslami M, Saidi RF. Current state of the art in management of vascular complications after pediatric liver transplantation. Pediatr Transplant 2015; 19 (01) 18-26
    CrossrefPubMedSuche in Google Scholar
  • 4 Werner MJM, de Meijer VE, Adelmeijer J. , et al. Evidence for a rebalanced hemostatic system in pediatric liver transplantation: a prospective cohort study. Am J Transplant 2020; 20 (05) 1384-1392
    CrossrefPubMedSuche in Google Scholar
  • 5 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365 (02) 147-156
    CrossrefPubMedSuche in Google Scholar
  • 6 Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116 (06) 878-885
    CrossrefPubMedSuche in Google Scholar
  • 7 Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007; 24 (04) 250-258
    CrossrefPubMedSuche in Google Scholar
  • 8 Arshad F, Lisman T, Porte RJ. Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. Liver Int 2013; 33 (06) 820-827
    CrossrefPubMedSuche in Google Scholar
  • 9 Lisman T, Caldwell SH, Burroughs AK. , et al; Coagulation in Liver Disease Study Group. Hemostasis and thrombosis in patients with liver disease: the ups and downs. J Hepatol 2010; 53 (02) 362-371
    CrossrefPubMedSuche in Google Scholar
  • 10 Werner MJM, de Kleine RHJ, de Boer MT. , et al. Routine postoperative antithrombotic therapy in pediatric liver transplantation: impact on bleeding and thrombotic complications. Thromb Haemost 2020; 120 (04) 627-637
    Thieme ConnectPubMedSuche in Google Scholar
  • 11 Srivastava P, Agarwal A, Jha A. , et al. Utility of prothrombin complex concentrate as first-line treatment modality of coagulopathy in patients undergoing liver transplantation: a propensity score-matched study. Clin Transplant 2018; 32 (12) e13435
    CrossrefPubMedSuche in Google Scholar
  • 12 Nacoti M, Corbella D, Fazzi F, Rapido F, Bonanomi E. Coagulopathy and transfusion therapy in pediatric liver transplantation. World J Gastroenterol 2016; 22 (06) 2005-2023
    CrossrefPubMedSuche in Google Scholar
  • 13 Kirchner C, Dirkmann D, Treckmann JW. , et al. Coagulation management with factor concentrates in liver transplantation: a single-center experience. Transfusion 2014; 54 (10 Pt 2): 2760-2768
    CrossrefPubMedSuche in Google Scholar
  • 14 Lisman T, Kleiss S, Patel VC. , et al. In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis. Liver Int 2018; 38 (11) 1988-1996
    CrossrefPubMedSuche in Google Scholar
  • 15 Tripodi A, Chantarangkul V, Primignani M. , et al. Thrombin generation in plasma from patients with cirrhosis supplemented with normal plasma: considerations on the efficacy of treatment with fresh-frozen plasma. Intern Emerg Med 2012; 7 (02) 139-144
    CrossrefPubMedSuche in Google Scholar
  • 16 Voulgarelis S, Vitola B, Lerret SM, Hong JC, Scott JP. Perioperative anticoagulation practices for pediatric liver transplantation. Pediatr Transplant 2018; 22 (04) e13193
    CrossrefPubMedSuche in Google Scholar
  • 17 Calinescu AM, Karam O, Wilde JCH, Ansari M, McLin VA, Wildhaber BE. International survey on anticoagulation and antiplatelet strategies after pediatric liver transplantation. Pediatr Transplant 2019; 23 (01) e13317
    CrossrefPubMedSuche in Google Scholar
  • 18 Ignjatovic V, Furmedge J, Newall F. , et al. Age-related differences in heparin response. Thromb Res 2006; 118 (06) 741-745
    CrossrefPubMedSuche in Google Scholar
  • 19 Monagle P, Ignjatovic V, Savoia H. Hemostasis in neonates and children: pitfalls and dilemmas. Blood Rev 2010; 24 (02) 63-68
    CrossrefPubMedSuche in Google Scholar
  • 20 Andrew M, Vegh P, Johnston M, Bowker J, Ofosu F, Mitchell L. Maturation of the hemostatic system during childhood. Blood 1992; 80 (08) 1998-2005
    CrossrefPubMedSuche in Google Scholar
  • 21 Northup P, Reutemann B. Management of coagulation and anticoagulation in liver transplantation candidates. Liver Transpl 2018; 24 (08) 1119-1132
    CrossrefPubMedSuche in Google Scholar
  • 22 Potze W, Arshad F, Adelmeijer J. , et al. Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis. PLoS One 2014; 9 (02) e88390
    CrossrefPubMedSuche in Google Scholar
  • 23 Potze W, Adelmeijer J, Lisman T. Decreased in vitro anticoagulant potency of rivaroxaban and apixaban in plasma from patients with cirrhosis. Hepatology 2015; 61 (04) 1435-1436
    CrossrefPubMedSuche in Google Scholar
  • 24 Hemker HC, Giesen P, Al Dieri R. , et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33 (01) 4-15
    CrossrefPubMedSuche in Google Scholar
  • 25 Lisman T, Porte RJ. Value of preoperative hemostasis testing in patients with liver disease for perioperative hemostatic management. Anesthesiology 2017; 126 (02) 338-344
    CrossrefPubMedSuche in Google Scholar
  • 26 Weeder PD, Porte RJ, Lisman T. Hemostasis in liver disease: implications of new concepts for perioperative management. Transfus Med Rev 2014; 28 (03) 107-113
    CrossrefPubMedSuche in Google Scholar
  • 27 Lisman T, Caldwell SH, Porte RJ, Leebeek FW. Consequences of abnormal hemostasis tests for clinical practice. J Thromb Haemost 2006; 4 (09) 2062-2063
    CrossrefPubMedSuche in Google Scholar
  • 28 Priyanka P, Kupec JT, Krafft M, Shah NA, Reynolds GJ. Newer oral anticoagulants in the treatment of acute portal vein thrombosis in patients with and without cirrhosis. Int J Hepatol 2018; 2018: 8432781
    CrossrefPubMedSuche in Google Scholar
  • 29 Lisman T, Kamphuisen PW, Northup PG, Porte RJ. Established and new-generation antithrombotic drugs in patients with cirrhosis - possibilities and caveats. J Hepatol 2013; 59 (02) 358-366
    CrossrefPubMedSuche in Google Scholar
  • 30 Maas H, Gropper S, Huang F. , et al. Anticoagulant effects of dabigatran in paediatric patients compared with adults: combined data from three paediatric clinical trials. Thromb Haemost 2018; 118 (09) 1625-1636
    Thieme ConnectPubMedSuche in Google Scholar
  • 31 Halton JML, Albisetti M, Biss B. , et al. Phase IIa study of dabigatran etexilate in children with venous thrombosis: pharmacokinetics, safety, and tolerability. J Thromb Haemost 2017; 15 (11) 2147-2157
    CrossrefPubMedSuche in Google Scholar
  • 32 Dietrich K, Stang L, van Ryn J, Mitchell LG. Assessing the anticoagulant effect of dabigatran in children: an in vitro study. Thromb Res 2015; 135 (04) 630-635
    CrossrefPubMedSuche in Google Scholar
  • 33 Ignjatovic V, Summerhayes R, Yip YY, Monagle P. The in vitro anticoagulant effects of danaparoid, fondaparinux, and lepirudin in children compared to adults. Thromb Res 2008; 122 (05) 709-714
    CrossrefPubMedSuche in Google Scholar
  • 34 Potze W, Arshad F, Adelmeijer J. , et al. Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis. Br J Haematol 2013; 163 (05) 666-673
    CrossrefPubMedSuche in Google Scholar
  • 35 Ninivaggi M, Apitz-Castro R, Dargaud Y, de Laat B, Hemker HC, Lindhout T. Whole-blood thrombin generation monitored with a calibrated automated thrombogram-based assay. Clin Chem 2012; 58 (08) 1252-1259
    CrossrefPubMedSuche in Google Scholar
  • 36 Senzolo M, Rodriguez-Castro KI, Rossetto V. , et al. Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis. J Thromb Haemost 2012; 10 (09) 1823-1829
    CrossrefPubMedSuche in Google Scholar